BackgroundObesity is a globally growing health problem, and its treatment has been challenging. The usage of antiobesity medications (AOMs) has been associated with severe adverse events (AEs). Spontaneous reports of AOMs can present detailed information about AEs occurring after the time of marketing. Several AOMs have been withdrawn from the market owing to documented AEs. ObjectiveTo estimate and characterize the frequency of AEs attributable to the use of the AOMs between January 2013 and June 2020.

No abstract

No abstract